XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Intangibles (Tables)
 6 Months Ended
Dec. 31, 2023
Text block [abstract]  
Summary of non-current assets - intangibles
    
Consolidated
  
    
December
2023
     
June 2023
  
    
$
     
$
  
Paxalisib Licensing agreement — at acquired fair value
      16,407,788        16,407,788  
Less: Accumulated amortisation
      (7,792,901 )       (7,250,728 ) 
  
 
 
     
 
 
  
     8,614,887        9,157,060  
  
 
 
     
 
 
  
EVT-801
Licensing agreement — at cost
      9,813,362        9,813,362  
Less: Accumulated amortisation
      (2,093,522 )       (1,700,990 ) 
  
 
 
     
 
 
  
     7,719,840        8,112,372  
  
 
 
     
 
 
  
     16,334,727        17,269,432  
  
 
 
     
 
 
  
Summary of reconciliations of intangibles
Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:
 
    
EVT801
licensing
agreement
      Paxalisib
licensing
agreement		      Total  
Consolidated    $      $      $  
Balance at 1 July 2023
      8,112,372        9,157,060        17,269,432  
Amortisation expense
      (392,532 )       (542,173 )       (934,705 ) 
  
 
 
     
 
 
     
 
 
  
Balance at 31 December 2023
      7,719,840        8,614,887        16,334,727